Abstract Background Behavioural studies in animal models represent a critical component of psychiatric drug development. Positive results in animal studies have identified novel therapeutic targets for major depressive disorder (MDD) but efficacy in humans has largely not been borne out in clinical trials. A possible reason for this failed translation is inappropriate dose selection and the...
In recent years, public and academic interest into psychedelics has increased, given the clinical evidence of their potential benefits for treating psychiatric conditions such as major depressive disorder (MDD). While this has been accompanied by several landmark human studies, mechanistic studies in rodents are still relatively few, but such studies are crucial for understanding the...
Psychedelic drugs have seen a resurgence in interest as a next generation of psychiatric medicines with potential as rapid-acting antidepressants (RAADs). Despite promising early clinical trials, the mechanisms which underlie the effects of psychedelics are poorly understood. For example, key questions such as whether antidepressant and psychedelic effects involve related or independent...